Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and the outcomes were inferior for patients with unfavorable-risk disease. This highlights the importance of prognostic testing for patients with CLL to guide treatment and improve outcomes. Introduction: Prognostic genetic testing is recommended for patients with chronic lymphocytic leukemia (CLL) to guide clinical management. Specific abnormalities, such as del(17p), del(11q), and unmutated IgHV, can predict the depth and durability of the response to CLL therapy. Patients and Methods: In the present analysis of the Connect CLL Registry (ClinicalTrials.gov identifier, NCT01081015), a prospective observational cohort study of patients treated across 199 centers, the patterns of prognostic testing and outcomes of patients with unfavorable-risk genetics were analyzed. From 2010 to 2014, 1494 treated patients were enrolled in the registry by line of therapy (LOT), and stratified by the results of cytogenetic/fluorescence in situ hybridization (FISH) Results: Cytogenetic/FISH testing was performed in 861 patients (58%) at enrollment; only 40% of these patients were retested before starting a subsequent LOT. Of those enrolled at the first LOT, unfavorable-risk patients had inferior event-free survival compared with favorable-risk patients (hazard ratio, 1.60; P ¼ .001). Event-free survival was inferior with bendamustine-containing regimens (P < .0001). Event-free survival did not differ significantly between risk groups for patients treated with ibrutinib or idelalisib in the relapse/refractory setting. The predictors of reduced eventfree survival included unfavorable-risk genetics, age 75 years, race, and treatment choice at enrollment. Conclusion: The present study has shown that prognostic cytogenetic/FISH testing is infrequently performed and
Introduction
Chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in Western countries. 1 It is often diagnosed in older patients, many of whom present with coexisting conditions. 1, 2 Clinical, genetic, and molecular markers can inform the prognosis in CLL. Genetic aberrations detected by fluorescence in situ hybridization (FISH) and karyotyping by metaphase cytogenetic testing provide important prognostic information for CLL patients that predict survival and disease progression. 3, 4 Thus, genetic prognostic testing is recommended for patients with newly diagnosed CLL 5, 6 because it can help to guide treatment selection, when indicated, and is useful for monitoring. 7 Recently updated prognostic models for use in patients with both early-and late-stage CLL also incorporate genetic testing results for risk stratification. [8] [9] [10] The presence of genetic abnormalities could have particular relevance when personalizing therapies and could influence the selection of immunochemotherapy regimens, kinase inhibitor therapies, stem cell transplantation, and/or eligibility for clinical trials for which the entry criteria include pre-existing molecular risk factors. 9, 11, 12 Additionally, the possibility of clonal evolution in CLL 13, 14 should trigger repeat genetic retesting by FISH and next-generation sequencing for TP53 mutation to guide subsequent lines of therapy. CLL patients with unfavorable-risk genetic markers represent a significant treatment challenge. Inferior outcomes have been observed in large clinical trials of patients with del(17p) 12 andto a lesser extent-those with del(11q) 15, 16 treated with combination chemoimmunotherapy. Complex karyotype detection by metaphase cytogenetic testing can also predict inferior outcomes in patients receiving ibrutinib-based therapy. 17 , 18 Byrd et al 19 also
reported inferior survival for ibrutinib-treated patients with del(17p) compared with patients with del(11q) and patients with neither abnormality. With the impressive array of CLL treatments now available, risk stratification has become increasingly useful and sophisticated in guiding treatment selection for patients. Real-world data from observational cohort studies have enhanced our understanding of treatment and outcomes for patients with CLL and can help to validate observations from clinical trials. To the best of our knowledge, the Connect CLL Registry is the largest prospective study describing the real-world management of a diverse cohort of patients with CLL in the United States. 20 In the present study, we describe the prognostic testing practices and factors influencing the decisions to perform FISH or cytogenetic testing in the Connect CLL registry. In addition, we describe the treatment selection and patterns of practices used in the treatment of unfavorable-risk patients to better understand the effect of risk stratification on treatment selection and outcomes for such patients in different practice settings.
Patients and Methods

Study Design
The Connect CLL Registry (ClinicalTrials.gov identifier, NCT01081015) is a large, US-based, multicenter, prospective observational cohort study. The primary objective was to observe the treatment patterns in patients with CLL. No study-specified treatment was required, and all interventions were performed at the discretion of the treating clinicians in accordance with their usual standard of care. Study centers with experience in oncology/hematology trials or registries and an adequate number of patients with CLL were invited to participate. The sites were encouraged to enroll all eligible patients as they presented to their physician; each center could enroll a maximum of 30 patients.
Patients
At enrollment, patients were required to be aged 18 years, provide written informed consent, and have CLL as defined by the International Workshop on CLL guidelines. 5 Only patients who initiated a new line of therapy (LOT) within the 2 months before study enrollment were eligible for inclusion. Patients undergoing active observation were ineligible. Full details on the design and conduct of the registry have been described previously. 20 
Assessments
For the purposes of the present analysis, patients were enrolled into 1 of 3 cohorts according to the LOT at enrollment: LOT1 (first LOT), LOT2 (second or further LOT), and LOT3 (third or further LOT). For some analyses, the LOT2 and LOT3 cohorts were pooled (LOT2 21, 22 All FISH/cytogenetic reports were centrally reviewed. The number of patients undergoing IgHV testing was too small to support a stratified analysis based on the risk level using IgHV status. Event-free survival was measured from study enrollment to the first occurrence of an event-free survival event (death, progression/ relapse, or transformation, excluding toxicity). Those patients who were still enrolled and did not experience an event were censored on August 25, 2015.
Statistical Analysis
To identify the characteristics associated with a decision to perform genetic testing at LOT1 and LOT2, univariate logistic regression was performed. Fourteen potential variables were evaluated, including LOT, Rai stage, age (< 75 vs. 75 years), health insurance status (private, Medicare, Medicaid, Military, self-pay), practice setting (academic, government, or community), household income, Eastern Cooperative Oncology Group performance status (ECOG PS) score, previous malignancy, race, geographic region, gender, and Charlson comorbidity index score. The variables identified on univariate analysis as significant at the P < .15 level were examined using stepwise multivariable logistic regression to identify the independent characteristics associated with a decision to perform genetic testing at either LOT1 or LOT2.
To identify the characteristics associated with inferior event-free survival, univariate Cox regression analysis was performed for patients enrolled at LOT1 and LOT2. Twenty-three potential predictors were evaluated, including genetic risk group, practice setting, age, race, gender, reasons for treatment initiation, enrollment therapy, and time from diagnosis to treatment. For patients enrolled at LOT2, enrollment at LOT2 (yes vs. no) was also included as a variable.
To identify the independent characteristics associated with inferior event-free survival, the variables identified on univariate Cox regression analysis as significant at the P < .15 level were included in a multivariable Cox regression analysis in a stepwise selection process. The results were further verified using subgroup scores to create a parsimonious model.
The Kaplan-Meier product-limit method was used to estimate the event-free survival and overall survival (OS) by risk group and by LOT at enrollment (LOT1 vs. LOT2). The P values from the log-rank test for comparison of the survival distributions were calculated. Statistical analyses of all data were performed using SAS version 9.2 statistical software (SAS Institute, Cary, NC).
Results
Patients
From March 2010 to January 2014, 1494 patients were enrolled in the Connect CLL Registry from 199 centers throughout the United States. 20 Of these, 179 were community-based centers (1311 patients), 17 were academic centers (155 patients), and 3 were government-based centers (28 patients). Of the total population, 889 patients were enrolled at LOT1, 260 patients at LOT2, and 345 patients at LOT3. The stratification of patients by risk category (unfavorable, favorable, or unknown) for patients enrolled at LOT1 or LOT2 is presented in Figure 1 . The demographic data and disease characteristics at enrollment for unfavorable-risk patients (by LOT1 or LOT2) are listed in Table 1 . Unfavorable-risk patients enrolled at LOT1 were older and more likely to have a favorable ECOG PS (0-1) and early-stage disease (Rai stage 0-II) than unfavorable-risk patients enrolled at LOT2.
Prognostic Testing and Practice Patterns
FISH and/or cytogenetic testing was performed at study enrollment in 861 patients (58%) overall (65% of patients at LOT1, 50% of patients at LOT2, and 45% of patients at LOT3; Table 2 ). Of the patients tested at enrollment who later received a subsequent LOT, only 40% were retested before starting a new LOT.
IgHV testing was performed at enrollment for only 95 patients (6.4%). Of these, 71 patients were enrolled at LOT1 and 24 at LOT2 (8% and 4% of all patients enrolled at LOT1 and LOT2, respectively; Supplemental Table 1 ; available in the online version).
As described previously, 20 having private insurance coverage, white race, and receiving care at an academic center were all independent predictors of undergoing FISH/cytogenetic testing (Table 3) . For the 601 patients enrolled at LOT1 and treated at a community/government center, white race, younger age, and Rai stage II each predicted the likelihood of a patient having FISH/ cytogenetic analysis. However, the data were insufficient to perform meaningful analyses on patients at LOT2. 
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Unfavorable-Risk Patients: Reasons for Initiating Treatment and Treatments Administered
The main reasons for initiating treatment (> 1 reason could be given) for unfavorable-risk patients in the LOT1 cohort were lymphadenopathy (41.8%), bone marrow failure (35.5%), and lymphocytosis (33.3%; Supplemental Table 2 ; available in the online version). The reasons for initiating treatment in LOT1 were similar across the 3 genetic risk groups. The most commonly prescribed therapies for unfavorable-risk patients at LOT1 were FCR (fludarabine, cyclophosphamide, rituximab; 35.5%), BR (bendamustine, rituximab; 20.6%), and FR (fludarabine, rituximab; 5.7%; Supplemental Table 3 ; available in the online version). At LOT1, unfavorable-risk patients were less likely to receive rituximab monotherapy compared with favorable-risk patients (4.3% vs. 9.9%; P ¼ .04). Because of the time at which this registry was conducted, no patient received ibrutinib-or idelalisib-containing therapy at LOT1.
The main reasons for initiating treatment for unfavorable-risk patients at LOT2 were relapse of CLL or primary resistance to LOT1 (73.8%), progressive bone marrow failure (36.9%), and progressive lymphocytosis (33.3%; Supplemental Table 2 ; available in the online version). The most commonly prescribed treatments administered to patients at LOT2 were BR (26.2%), rituximab monotherapy (10.7%), and FCR (9.5%; Supplemental Table 3 ; available in the online version). At LOT2, unfavorable-risk patients were more likely to receive rituximab monotherapy (10.7% vs. 8.7%) and an investigational product administered as part of a clinical trial (7.1% vs. 4.1%) compared with favorable-risk patients. Overall, 10% of unfavorable-risk patients participated in a clinical trial and 4% underwent allogeneic stem cell transplantation during the present study.
Event-free Survival Stratified by Risk Factors and LOT
At the present analysis, 798 patients (53.4%) experienced an event-free survival event; 364 (40.9%) during LOT1 and 434 (71.7%) during LOT2. The most commonly occurring event-free survival events were progression/relapse (LOT1, 72.5%; LOT2, 72.6%) and death (LOT1, 23.9%; LOT2, 24.7%). Of the patients enrolled at LOT1, 71 unfavorable-risk patients (50%) experienced an event-free survival event versus 153 favorable-risk patients (36%). Kaplan-Meier curves for event-free survival for unfavorable-risk patients versus favorable-risk patients enrolled at LOT1 and LOT2 are shown in Figure 2 . Unfavorable-risk patients had significantly worse event-free survival compared with favorable-risk patients, in the LOT1 (hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.21-2.12; P ¼ .001) and LOT2 (HR, 1.66; 95% CI, 1.23-2.24; P ¼ .0009) groups both. For patients with del(17p) or del(11q), the risk of an event-free survival event was not significantly different in LOT1 regardless of whether they had been treated with BR or FCR (HR, 0.85; 95% CI, 0.54-1.35; P ¼ .50).
Event-free Survival and OS Stratified by Therapy
In patients receiving FCR or FR chemoimmunotherapy at LOT1, a trend toward lower event-free survival was seen for unfavorable-risk compared with favorable-risk patients (P ¼ .08; Figure 3A ). Event-free survival was also lower for unfavorableversus favorable-risk patients treated with BR (P < .0001; Figure 3B ). Event-free survival for patients treated with FCR or BR at LOT2 could not be estimated because of low patient numbers. 
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Of the 163 patients treated with a kinase inhibitor at LOT2, event-free survival was not significantly different for the unfavorable-risk versus favorable-risk patients receiving ibrutinib-or idelalisib-based therapy (P ¼ .49). When adjusted for the number of therapies received before a kinase inhibitor and patient age at enrollment, no significant difference in event-free survival between risk groups was found in patients treated with ibrutinib-or idelalisib-based therapy in the relapsed/refractory setting (HR, 0.69; 95% CI, 0.23-2.10; P ¼ .52).
No significant difference was found in OS between the unfavorable-and favorable-risk patients treated with FCR-or BR-containing regimens at LOT1 (P ¼ .38 and P ¼ .42, respectively) nor between unfavorable-and favorable-risk patients receiving ibrutinib-or idelalisib-based therapies at LOT2 (P ¼ .23). No significant difference in OS between risk groups was found after adjusting for the number of previous therapies and patient age at enrollment (P ¼ .32). Risk group was not a significant predictor of OS for patients treated with kinase inhibitors as assessed by Cox regression analysis (P ¼ .51).
Predictors of Inferior Event-free Survival
Univariate analyses were performed to identify the variables associated with inferior event-free survival (P < .15). For patients Table 3 ; available in the online version).
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Figure 3 Kaplan-Meier Curves for Event-Free Survival in Unfavorable-Risk and Favorable-Risk Patients at First Line of Therapy (LOT1). (A) Event-Free Survival for Patients Receiving FCR (Fludarabine, Cyclophosphamide, Rituximab). (B) Event-Free Survival for Patients Receiving BR (bendamustine, rituximab)
Abbreviation: CI ¼ confidence interval.
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enrolled at LOT1, 11 variables were associated with inferior eventfree survival, including unfavorable-risk group, non-white race, age 75 years, CD38 þ CLL, previous malignancy, Charlson comorbidity index score 3, non-private insurance coverage, and choice of enrollment therapy other than chemoimmunotherapy (ie, anti-CD20 monoclonal antibody therapy or chlorambucil monotherapy). For patients at LOT2, the following variables were associated with inferior event-free survival: unfavorable-risk group, community/government practice setting, ECOG PS 1, LOT3, thrombocytopenia or progressive bone marrow failure as a reason for treatment initiation, and choice of enrollment therapy other than chemoimmunotherapy. On multivariable analysis of the patients enrolled at LOT1, 5 significant independent predictors of inferior event-free survival were identified: unfavorable-risk genetics, non-white race, age 75 years, enrollment treatment other than chemoimmunotherapy, and previous malignancy (Table 4 ). For patients enrolled at LOT2, unfavorable-risk group and community/government practice setting were significant independent predictors of inferior event-free survival (HR, 1.83; 95% CI, 1.35-2.49; P < .0001; and HR, 2.27; 95% CI, 1.39-3.71; P ¼ .001, respectively).
Discussion
To the best of our knowledge, the Connect CLL Registry is the largest US registry of CLL patients undergoing active therapy. It includes 1494 patients undergoing therapy who were prospectively enrolled from 2010 to 2014 and, to date, treated at 199 centers with a broad US geographic representation. However, in the present analysis, only 58% of patients had had FISH/cytogenetic testing performed at enrollment, despite all patients beginning a new LOT within the 2 months before registry enrollment. Furthermore, although the CLL clone can acquire new genetic abnormalities over time, only 40% of patients who were tested initially and who received a subsequent therapy were retested before the new LOT was started. Additionally, IgHV testing at enrollment was performed for only 6.4% of patients. Although IgHV testing was reported more frequently by academic centers than by community/ government centers, the levels of IgHV testing were still surprisingly low in the academic settings (11%). This might have been because IgHV testing is performed separately from standard FISH testing. To perform IgHV testing routinely in all patients, it might be useful to group FISH and IgHV testing together in the electronic medical record systems.
Despite the recognized importance of genetic testing in determining the CLL prognosis and management, 5 it appears that patients in the real-world treatment setting might be undergoing prognostic testing at a lower rate than expected. These data suggest that the likelihood of performing FISH/cytogenetic testing was influenced by insurance coverage, race, and type of treatment center, indicating a role for continued awareness and the need for intensive education regarding the value of this information at diagnosis and relapse. Not surprisingly, patients with unfavorable-risk CLL enrolled at LOT1 and LOT2 had inferior event-free survival compared with favorable-risk patients. Furthermore, unfavorable risk was an independent predictor of inferior event-free survival in the multivariable analyses for patients at LOT1 and LOT2. These real-world results validate data from several landmark clinical trials showing inferior outcomes for patients with unfavorable-risk genetics treated with chemoimmunotherapy combinations. 12, 15, 16 This was important to validate in a large patient population not treated in the context of a clinical trial and to support the generalizability of findings obtained for unfavorable-risk CLL patients in large chemoimmunotherapy clinical trials. These findings also underscore the importance of performing genetic risk stratification in all CLL patients when making treatment decisions. This is particularly important in light of the approval of treatment options that are effective in patients with del(17p)-positive CLL. Although no difference in OS between favorable-and unfavorable-risk patients receiving chemoimmunotherapy was observed, this was likely because of the short follow-up time available for the present analysis. The ability of unfavorable-risk patients to achieve durable responses with kinase inhibitor therapies in the relapse setting might also impact OS. Several studies have highlighted the importance of prognostic testing in the management of CLL patients. In the present study, the following 5 predictors for inferior event-free survival at LOT1 were identified on multivariable analysis: unfavorable-risk genetics, non-white race, age 75 years, enrollment treatment other than chemoimmunotherapy, and previous malignancy. These results are in line with previous studies, which have found that treatment other than chemoimmunotherapy and African-American race are independent predictors of inferior event-free survival and/or progressionfree survival. 23, 24 Older age ( 55 years or 65 years) was not an independent predictor of progression-free survival in other studies. 11, 12, 23 The results from the CLL8 trial showed improved OS but not progression-free survival for younger patients (age < 65 years) treated with FCR. 23 However, event-free survival was not assessed as an outcome in these studies. Del(17p) has been associated with poor overall response rates to fludarabine/cyclophosphamide and to FCR.
12 Del(11q) has also been associated with more rapid disease progression and inferior survival in younger patients, 15 and patients with a complex karyotype have inferior survival when treated with ibrutinib-containing therapies. [17] [18] [19] 25 IgHV mutational status is predictive of the time to first treatment, with unmutated IgHV predictive of a shorter time to the first treatment. 10, 26 Three recent updates on patients treated with FCR suggested that patients with mutated IgHV without del(17p) can have durable remission, with the median progression-free survival not reached after a follow-up period of 5.8 to 12.8 years. 23, 25, 27 The presence of del(17p) and unmutated IgHV mutation status have also been associated with inferior progression-free survival in previously untreated patients undergoing treatment with BR. 28 Our data suggest that genetic testing was not uniformly performed across the participating sites. Although most patients were enrolled in community-based centers, enrollment at an academic versus community/government center was a significant predictor of FISH/cytogenetic testing. This might reflect lower patient socioeconomic status or greater barriers to testing at community centers versus academic sites. Private insurance coverage was also a predictor of FISH/cytogenetic testing, which might also reflect or contribute to the apparent socioeconomic barrier to testing. At community/government centers specifically, younger patients with more advanced disease (Rai stage II) were more likely to undergo genetic testing when enrolled at LOT1. The low number of patients undergoing genetic testing is consistent with a recent study in Italy in which only 25% of patients underwent FISH, IgHV, and b 2 -microglobulin testing. 28 When selecting treatment, unfavorable-risk patients should be considered for participation in clinical trials and/or for treatment using novel agents, such as B-cell receptor pathway kinase inhibitors or B-cell lymphoma-2 antagonists. However, only 10% of unfavorable-risk patients in the Connect CLL Registry and < 5% of patients overall were enrolled in clinical trials at enrollment to the registry. 20 This might reflect a lack of CLL studies available at participating sites and limited opportunities for patients to enroll in a clinical trial.
As the Connect CLL Registry predates the widespread use of ibrutinib and idelalisib, limited numbers of patients were treated with these agents. Of 163 patients treated with ibrutinib or idelalisib in the relapsed/refractory setting, event-free survival and OS did not differ significantly between patients with favorable-risk and unfavorable-risk genetics. These results confirm previous observations that these agents partially overcome traditional unfavorablerisk genetic features of CLL. 29, 30 With longer follow-up, we expect that the outcomes for patients with del(17p) and del(11q), although excellent compared with historical controls, are likely to be inferior to those in patients with more favorable-risk genetic features; this has been demonstrated by Byrd et al 19 and O'Brien et al. 31 Additional studies are needed to assess the long-term treatment patterns and outcomes of unfavorable-risk CLL patients in the era of B-cell receptor-targeted agents. The InformCLL Registry (ClinicalTrials.gov identifier, NCT02582879) will provide more detail on the experiences of patients and physicians using oral kinase inhibitors and B-cell lymphoma-2 inhibitors. With physicians becoming increasingly familiar with prescribing ibrutinib and idelalisib, more real-world data on these novel agents will become available. The present registry-based study had several limitations. To ensure that the patient population was as representative of the overall US population as feasible, the Connect CLL Registry enrolled patients from a large number of geographically diverse and primarily community-based centers throughout the United States. In observational cohort studies, the absence of treatment randomization might lead to a bias in patient selection. Treating physicians are not required to follow formal response criteria, which could also have affected treatment selection and assessment of treatment effectiveness. Underreporting or missing data could also be a potential source of bias. Because most patients initiated therapy before enrollment, the potential exists for diagnostic testing to have been underreported. However, we found only 20% of patients initiated treatment > 30 days before enrollment. To minimize missing or erroneous data, the data were reviewed and queried on a regular basis. To further minimize the selection bias, the personnel at sites were educated to consecutively enroll patients beginning treatment, regardless of medical history or ECOG PS. Nevertheless, at enrollment to the Connect CLL Registry, most patients had an ECOG PS 1 and were insured either through the Medicare program or privately.
Conclusion
Data from the Connect CLL Registry highlight the need for increased education and awareness of the importance of genetic and molecular prognostic testing in patients with CLL. This is particularly true for older patients, those treated in the community setting, those lacking private insurance coverage, and those with lower socioeconomic status. At the time of treatment decisionmaking, genetic and molecular data are critical to select the most appropriate therapy for an individual patient and can be useful in identifying patients as candidates for clinical trials targeting genetically unfavorable-risk disease. Inferior outcomes with chemoimmunotherapy in unfavorable-risk patients were observed compared with favorable-risk patients, supporting the findings from landmark clinical trials. Additionally, the presence of del(17p) and del(11q) was validated as an independent predictor of inferior eventfree survival in the front line and relapse settings. In 163 patients treated with a kinase inhibitor in the relapsed/refractory setting, our real-world data have confirmed reports from recent clinical trials that these agents can partially overcome unfavorable-risk features of CLL and are the standard of care for CLL patients with unfavorablerisk genetics.
Clinical Practice Points
In the real-world setting, patients with unfavorable-risk genetics had worse survival on chemoimmunotherapy; this was overcome by kinase inhibitor (ibrutinib or idelalisib) treatment. Kinase inhibitor therapies can overcome, in part, the poor-risk features of CLL. Although prognostic genetic testing is an important tool to guide treatment in patients with CLL, such testing was infrequently performed among patients with CLL treated in the community setting. Private insurance coverage, white race, and receiving care at an academic center were all independent predictors of undergoing FISH/cytogenetic testing. These findings highlight the importance of completing prognostic genetic testing for all CLL patients and suggest the need for continued awareness and education regarding the value of this information at diagnosis and relapse. 
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